X4 Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by X4 Pharmaceuticals, Inc. on November 9, 2022, covering events occurring on November 7, 2022. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Boston, Massachusetts. Its common stock trades on the Nasdaq Capital Market under the symbol "XFOR".
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on executive compensation arrangements.
Material Changes and Events
On November 7, 2022, the Compensation Committee approved special retention and recognition grants of Stock Appreciation Rights (SARs) to key executive officers under the Company's Amended and Restated 2017 Equity Incentive Plan.
- Grant Price: $1.80 per SAR (based on the closing stock price on the Grant Date).
- Term: Maximum of ten years from the Grant Date.
- Settlement: SARs will be settled in cash upon exercise unless otherwise determined by the Board.
- Vesting Schedule: Equal annual installments over three years (first, second, and third anniversaries), subject to continued employment.
- Acceleration: Full vesting occurs upon a Change of Control if the recipient remains employed through the transaction date.
Grant Allocation:
| Recipient | Title | SARs Awarded |
|---|---|---|
| Paula Ragan, Ph.D. | President and CEO | 3,438,335 |
| Adam S. Mostafa | CFO and Treasurer | 1,350,000 |
| Other Executive Officers | Various | 2,350,000 |
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, operational outlook, or specific risk factors beyond the standard terms of the equity incentive plan. The primary contingency noted is the requirement for continued employment to maintain vesting schedules, with an exception for Change of Control events.
Key Facts for Investor Verification
- Verify the total number of SARs granted (7,138,335) and the associated potential cash liability upon exercise.
- Confirm the current stock price relative to the $1.80 grant price to assess the immediate intrinsic value of these awards.
- Review the "Change of Control" definition in the attached Stock Appreciation Right Agreement (Exhibit 10.1) to understand acceleration triggers.
- Note that this filing does not report any changes in the Company's financial position or operational results.